APE1/Ref-1作为炎症性肠病的治疗点
Lauren Sahakian1, Ainsley M Robinson1, Linda Sahakian2
1Institute for Health & Sport, Victoria University, Melbourne, VIC 3021, Australia.
需要针对炎症性肠病 (IBD) 的新疗法. 针对apurinic/apyrimidinic内核酶1/减氧因子1 (APE1/Ref-1) 的氧化还原活性,对IBD治疗具有前景.
科学领域:
- 胃肠病学 胃肠病学
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 炎症性肠病 (IBD) 影响全球数以百万计的人,患病率越来越高.
- 目前的IBD疗法具有显著的副作用和长期毒性.
- 对于IBD的新型治疗策略有着至关重要的需求.
研究的目的:
- 审查常规IBD治疗方法.
- 探索 apurinic/apyrimidinic 内核酶1/减氧因子1 (APE1/Ref-1) 在肠道炎症中的作用.
- 评估APE1/Ref-1氧化还原活性抑制作为一种新型IBD治疗的潜力.
主要方法:
- 对当前IBD治疗方法的文献综述.
- 分析APE1/Ref-1在炎症途径和转录因子调节中的作用.
- 针对APE1/Ref-1氧化还原活性的小分子抑制剂的讨论.
主要成果:
- APE1/Ref-1 调节了参与炎症途径的关键转录因子.
- 抑制APE1/Ref-1的氧化还原功能可能会调节炎症和氧化应激.
- 针对APE1/Ref-1可能会减少IBD中的肠神经元损伤.
结论:
- APE1/Ref-1 是IBD的一个有前途的治疗点.
- APE1/Ref-1氧化还原活性的小分子抑制剂需要进一步研究IBD治疗.
- 调节APE1/Ref-1提供了一个潜在的策略来解决IBD中的炎症,氧化应激和神经元损伤.
更多相关视频
07:05Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation
Published on: December 15, 2017
09:08Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies
Published on: June 2, 2021
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
